newsfilter
← Latest News
ClinicalTrials.gov·

Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1910 in Healthy Participants - NCT05307978

Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs), Maximum Observed Serum Concentration (Cmax), Time to Maximum Observed Serum Concentration (Tmax), (and 4 more...)